... Gianni Sicilian, Venetian
Graziano, Enzo Campania Beppe
Bolzano, Robi Faenza, Rimini
Adolfo, Mark Tuscan Romagna
Bobbi ....
Thursday, March 17, 2011
Remington 870 Receiver Blueprints
UNIT 'D' ITALY
Wednesday, March 16, 2011
Is Your Cervix Low Right Before Af
Nerviano Medical Sciences, new licensing agreement with Novartis
From Republic Business and Finance:
(AGI) - Rome, March 15 - Nerviano Medical Sciences (NMS), the largest center for research and drug development in Italy and one of the leading integrated production and drug development in Europe in the field oncology, today announced a new licensing agreement with Novartis. With this agreement, the statement said, Nerviano Medical Sciences gave Novartis exclusive licensing rights to develop a series of compounds belonging to the cancer center. Novartis will have the responsibility to conduct further research on the subject of the molecules, as well as development and marketing.
Given the exclusive license, Novartis will pay Nerviano to an initial sum, the milestones of success and subsequent royalties on each product sold. Further details and financial terms were not disclosed.
"We are very proud of this new agreement with Novartis, a leading global healthcare market, which marks the achievement of a significant new milestone for commercial Nerviano," said Alberto Sciumè, President of Nerviano Medical Sciences. "This is the second licensing agreement signed by Nerviano Medical Sciences from the beginning of 2011. The first agreement was signed with Genentech January 18, 2011, to permit molecules to the development of inhibitors of new pharmacological targets. I am convinced that 'experience Nerviano and expertise in the discovery of new small molecules may contribute to innovation and development of value products for the oncology market. "
Nerviano Medical Sciences, new licensing agreement with Novartis
The Republic
(AGI) - Rome, March 15 - Nerviano Medical Sciences (NMS), the largest center for research and drug development in Italy and one of the most important ...
Nerviano Medical Sciences announces a new licensing agreement
Business Wire
With this agreement, Nerviano Medical Sciences gave Novartis exclusive licensing rights to develop a series of compounds cancer of the property ...
Tumors: Novartis agreement for drug-Nms
ANSA.it
(ANSA) - MILAN, MARCH 15 - Agreement between the cancer research center in Milan Nerviano Medical Sciences (NMS) with the multinational Novartis to bring .. . 
From Republic Business and Finance:
(AGI) - Rome, March 15 - Nerviano Medical Sciences (NMS), the largest center for research and drug development in Italy and one of the leading integrated production and drug development in Europe in the field oncology, today announced a new licensing agreement with Novartis. With this agreement, the statement said, Nerviano Medical Sciences gave Novartis exclusive licensing rights to develop a series of compounds belonging to the cancer center. Novartis will have the responsibility to conduct further research on the subject of the molecules, as well as development and marketing.
Given the exclusive license, Novartis will pay Nerviano to an initial sum, the milestones of success and subsequent royalties on each product sold. Further details and financial terms were not disclosed.
"We are very proud of this new agreement with Novartis, a leading global healthcare market, which marks the achievement of a significant new milestone for commercial Nerviano," said Alberto Sciumè, President of Nerviano Medical Sciences. "This is the second licensing agreement signed by Nerviano Medical Sciences from the beginning of 2011. The first agreement was signed with Genentech January 18, 2011, to permit molecules to the development of inhibitors of new pharmacological targets. I am convinced that 'experience Nerviano and expertise in the discovery of new small molecules may contribute to innovation and development of value products for the oncology market. "
Nerviano Medical Sciences, new licensing agreement with Novartis
The Republic
(AGI) - Rome, March 15 - Nerviano Medical Sciences (NMS), the largest center for research and drug development in Italy and one of the most important ...
Nerviano Medical Sciences announces a new licensing agreement
Business Wire
With this agreement, Nerviano Medical Sciences gave Novartis exclusive licensing rights to develop a series of compounds cancer of the property ...
Tumors: Novartis agreement for drug-Nms
ANSA.it
(ANSA) - MILAN, MARCH 15 - Agreement between the cancer research center in Milan Nerviano Medical Sciences (NMS) with the multinational Novartis to bring .. .
Monday, March 7, 2011
Where Can I Buy Hot Cheetos Asteroids
where we are ...
It 's a bit that I want to come back to talk about work, and have the opportunity at hand. Here's what they tell me:
"We received a response to availability of collaboration:"
(Who receives the answer is not a young apprentice, but a couple of craftsmen with decades of experience and a track record over)
\u0026lt;\u0026lt;Would you be free for a week of testing ? The next?
We Val ... ... 5.5 days working unpaid , test. Room and board course offered .>>
(Cooome course offered? God forbid, do not pay them and they should also think about lunch?)
(They, the artisans who receive a proposal , are Rimini, about 500 km from there. At lunch the bidders but we thought the trip you fend well.)
"And these are not the usual \u0026lt;\u0026lt;caimani>> but people \u0026lt;\u0026lt;alternativa>> that promotes live \u0026lt;\u0026lt;misura d'uomo> >...\u0026lt;\u0026lt; because we only build with different materials,>> say, \u0026lt;\u0026lt;but with a different spirit from Conventional>>
(Well different is different: you work I you do not pay)
\u0026lt;\u0026lt;E 'we have to evaluate several teams ... let us know the availability ...>>>
(That way there for organizations from start to finish the job and free)
This is what happens to us men (write to me friends)
Happy March to you all eight women.
(We often happens even worse, come on guys, at least they have not even asked to let them see)
( 
Thursday, March 3, 2011
Free Abortion Clinics In Boston
With virtual reality, you choose the molecule to beat cancer
From Corriere della Sera on March 3:
Computer simulations can help to choose the most effective anticancer drugs for individual patients
MILAN - cancer treatment is better with virtual reality. Easy to say, harder to understand, but is explained by the researchers of the Institute of Cancer in Milan with a news item appeared on a famous magazine, Nature Review in Clinical Oncology, which demonstrates how computer simulations can help to choose the most effective anticancer drugs for individual patients. Starting point: cancer cells have on their surface molecules (receptors), which are the target of new anticancer molecules. The latter, by binding to the receptor, blocking tumor growth. But things do not always work well. The tumor tries to 'resist' to treatment in a kind of evolutionary adaptation, changing the shape of its receptors: At this point the drug becomes ineffective. So it is essential to look for others.
receptor in 3D - Now, thanks to computer modeling, it is possible to reconstruct not only the receptor of the tumor in three dimensions, but also the drug, and assess when the two fit together perfectly like a puzzle (in this case the drug is effective) or when no longer fit (and that means the treatment has stopped working). "Our study concerns a particular type of tumor, the Gist - explains Marco Pierotti, scientific director of the cancer - which develops on the walls of the digestive system by connective tissue cells and is characterized by two receptors, called Kit and PDGFR-A. On these two imatinib is active. We have reconstructed in 3D computer, or the two receptors that the drug, studying their interactions. " Answers computer (we used the network of the University of Trieste) were then verified in clinical practice: When the computer reports, models of virtual ineffectiveness of the drug on the patient it stops working.
NEW MOLECULE - "The experiment - continued Pierotti - he suggested three things. In a case of increasing the dose of medication and this worked. In another, became "resistant" to imatinib, we tested a new molecule that has been effective, the computer first, then the patient. The last suggestion concerns the search for the future. " The idea, in fact, is to play at the computer, all possible modifications of receptors of a tumor, even those not yet appeared in nature, and to study, always with virtual reality, the interactions of the receptors 'changed' with a number of new drugs, to evaluate their effectiveness. It is a research project that involves the Nerviano Medical Sciences. The center of Lombard will offer his "library" of more than 65 000 molecules, all potential anticancer drugs, and the computer will monitor those assets. It can thus be assumed to create anti-cancer cocktail capable of fighting all the mutations of the tumor, even those that are not yet known.
Read the original article 
From Corriere della Sera on March 3:
Computer simulations can help to choose the most effective anticancer drugs for individual patients
MILAN - cancer treatment is better with virtual reality. Easy to say, harder to understand, but is explained by the researchers of the Institute of Cancer in Milan with a news item appeared on a famous magazine, Nature Review in Clinical Oncology, which demonstrates how computer simulations can help to choose the most effective anticancer drugs for individual patients. Starting point: cancer cells have on their surface molecules (receptors), which are the target of new anticancer molecules. The latter, by binding to the receptor, blocking tumor growth. But things do not always work well. The tumor tries to 'resist' to treatment in a kind of evolutionary adaptation, changing the shape of its receptors: At this point the drug becomes ineffective. So it is essential to look for others. receptor in 3D - Now, thanks to computer modeling, it is possible to reconstruct not only the receptor of the tumor in three dimensions, but also the drug, and assess when the two fit together perfectly like a puzzle (in this case the drug is effective) or when no longer fit (and that means the treatment has stopped working). "Our study concerns a particular type of tumor, the Gist - explains Marco Pierotti, scientific director of the cancer - which develops on the walls of the digestive system by connective tissue cells and is characterized by two receptors, called Kit and PDGFR-A. On these two imatinib is active. We have reconstructed in 3D computer, or the two receptors that the drug, studying their interactions. " Answers computer (we used the network of the University of Trieste) were then verified in clinical practice: When the computer reports, models of virtual ineffectiveness of the drug on the patient it stops working.
NEW MOLECULE - "The experiment - continued Pierotti - he suggested three things. In a case of increasing the dose of medication and this worked. In another, became "resistant" to imatinib, we tested a new molecule that has been effective, the computer first, then the patient. The last suggestion concerns the search for the future. " The idea, in fact, is to play at the computer, all possible modifications of receptors of a tumor, even those not yet appeared in nature, and to study, always with virtual reality, the interactions of the receptors 'changed' with a number of new drugs, to evaluate their effectiveness. It is a research project that involves the Nerviano Medical Sciences. The center of Lombard will offer his "library" of more than 65 000 molecules, all potential anticancer drugs, and the computer will monitor those assets. It can thus be assumed to create anti-cancer cocktail capable of fighting all the mutations of the tumor, even those that are not yet known.
Read the original article
Wednesday, March 2, 2011
Shostak Vocab Level F Answers
CANCER: STUDY THE ITALIAN REALITY 'TO FIGHT EVEN IF VIRTUAL
INT MILAN 3D SUPERCOMPUTER SIMULATIONS TO DISCOVER 'COCKTAIL' TO DRUGS MADE
Milan, March 2 (Adnkronos / Adnkronos Health) - Against the wiles of the cancer, the Italian research group reality 'virtual. With the help of special supercomputer, and 'possible to discover in advance the' cocktail 'of drugs to be administered simultaneously to tailor therapies to remain effective even when the tumor changes, changing its architecture to escape the treatment. The effectiveness of this approach, based on simulations in 3D, and 'has been demonstrated by scientists at the National Cancer Institute (Int) in Milan in a study published in' Nature Reviews Clinical Oncology '.
The research, coordinated by the Director the Int scientific Marco Pierotti and presented today at a meeting all'Irccs Via Venezian, and 'was conducted in collaboration with the University' of Trieste and funds of the Italian Association for Cancer Research (AIRC). The method 'was applied to GIST (gastrointestinal stromal tumors), a family of rare tumors that develop on the walls of the digestive system, but the goal is' to extend in the near future to all types of cancer. Including so-called 'big killer'.
Thanks to an alliance with Nerviano Medical Sciences (NMS), the maxi-pole on the outskirts of Milan entered the oncology network london (Rol) , "in a couple of years - an estimate Pierotti - we hope to get to first treatment being developed using this innovative system. "
GOAL CHOOSE 'desk' THE MIX ANTI-RESISTANCE
To resist drugs cancer evolves and changes, changing its molecular structure so as to counteract the therapy . With the new technique, experts assure the Int of Milan, not only can predict future changes of the tumor, but you can also select 'on table' blend of therapeutic ingredients that can fight cancer once it changes .
To demonstrate the effectiveness of this approach Pierotti and colleagues chose Gist tumors, caused by the activation of two receptors called crazy Kit and PDGFR-A. To 'extinguish' ad hoc medicines already exist (in this case the researchers used the blockbuster imatinib, known as the founder of so-called smart drugs
), but when the tumor outline Kit and PDGFR-A change shape and the drug can no longer to hook them perfectly. In other words, the cancer becomes resistant to treatment. While
to bypass the problem with traditional techniques long used in vitro experiments - trying different molecules one by one until he finds one that matches the receptors changed - with the supercomputer time they fall away. Using a network of 'brains' willing to Trieste, the researchers were able to reconstruct virtual models Milan 3D
receptor target both the normal and mutated. Thus, in simulations carpet have tried to 'catch' with different medications, until it snaps perfect lock and key.
Nerviano Medical Sciences ALLY FOR NEW THERAPIES
"The model predictions about which molecules would be effective against tumors changed - says Pierotti - have been fully confirmed by observations in the laboratory and also from therapy in the patient using a specified
drug identified by the 3D models we were able to record improvements, also documented by images obtained with the CT / PET.
E "because in theory it is possible to foresee all possible mutations receptor of cancer, then draw three-dimensional models in virtual reality - adds the scientific director of the Int Milan - our future goal is to put every possible mutation in comparison with potentially active molecules,
to find all those that fit perfectly " . The screening will take advantage of the alliance with Nerviano Medical Sciences and its 'library', a mega-archvio with "about 65 000 drug candidates," says Pierotti .
"Then - concluded the scientist - once identified molecules better suited to deal with any mutation of the tumor, you can create cocktails of drugs effective in the long term. Giving all the molecules effective at the same time, we will be able to fight all mutations, even those who do not yet have occurred. " 
INT MILAN 3D SUPERCOMPUTER SIMULATIONS TO DISCOVER 'COCKTAIL' TO DRUGS MADE
Milan, March 2 (Adnkronos / Adnkronos Health) - Against the wiles of the cancer, the Italian research group reality 'virtual. With the help of special supercomputer, and 'possible to discover in advance the' cocktail 'of drugs to be administered simultaneously to tailor therapies to remain effective even when the tumor changes, changing its architecture to escape the treatment. The effectiveness of this approach, based on simulations in 3D, and 'has been demonstrated by scientists at the National Cancer Institute (Int) in Milan in a study published in' Nature Reviews Clinical Oncology '.
The research, coordinated by the Director the Int scientific Marco Pierotti and presented today at a meeting all'Irccs Via Venezian, and 'was conducted in collaboration with the University' of Trieste and funds of the Italian Association for Cancer Research (AIRC). The method 'was applied to GIST (gastrointestinal stromal tumors), a family of rare tumors that develop on the walls of the digestive system, but the goal is' to extend in the near future to all types of cancer. Including so-called 'big killer'.
Thanks to an alliance with Nerviano Medical Sciences (NMS), the maxi-pole on the outskirts of Milan entered the oncology network london (Rol) , "in a couple of years - an estimate Pierotti - we hope to get to first treatment being developed using this innovative system. "
GOAL CHOOSE 'desk' THE MIX ANTI-RESISTANCE
To resist drugs cancer evolves and changes, changing its molecular structure so as to counteract the therapy . With the new technique, experts assure the Int of Milan, not only can predict future changes of the tumor, but you can also select 'on table' blend of therapeutic ingredients that can fight cancer once it changes .
To demonstrate the effectiveness of this approach Pierotti and colleagues chose Gist tumors, caused by the activation of two receptors called crazy Kit and PDGFR-A. To 'extinguish' ad hoc medicines already exist (in this case the researchers used the blockbuster imatinib, known as the founder of so-called smart drugs
), but when the tumor outline Kit and PDGFR-A change shape and the drug can no longer to hook them perfectly. In other words, the cancer becomes resistant to treatment. While
to bypass the problem with traditional techniques long used in vitro experiments - trying different molecules one by one until he finds one that matches the receptors changed - with the supercomputer time they fall away. Using a network of 'brains' willing to Trieste, the researchers were able to reconstruct virtual models Milan 3D
receptor target both the normal and mutated. Thus, in simulations carpet have tried to 'catch' with different medications, until it snaps perfect lock and key.
Nerviano Medical Sciences ALLY FOR NEW THERAPIES
"The model predictions about which molecules would be effective against tumors changed - says Pierotti - have been fully confirmed by observations in the laboratory and also from therapy in the patient using a specified
drug identified by the 3D models we were able to record improvements, also documented by images obtained with the CT / PET.
E "because in theory it is possible to foresee all possible mutations receptor of cancer, then draw three-dimensional models in virtual reality - adds the scientific director of the Int Milan - our future goal is to put every possible mutation in comparison with potentially active molecules,
to find all those that fit perfectly " . The screening will take advantage of the alliance with Nerviano Medical Sciences and its 'library', a mega-archvio with "about 65 000 drug candidates," says Pierotti .
"Then - concluded the scientist - once identified molecules better suited to deal with any mutation of the tumor, you can create cocktails of drugs effective in the long term. Giving all the molecules effective at the same time, we will be able to fight all mutations, even those who do not yet have occurred. "
Sunday, February 13, 2011
Subscribe to:
Posts (Atom)